An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma
Email for information
Research Start Date
This joint research project will benefit the Collaborating Party by accomplishing its mission to promote and support the advancement of military medicine and specifically military medical research. The project will benefit the Federal Laboratory by providing valuable research experience for the staff involved. In addition, patients at BAMC with relapsed or refractory follicular lymphoma may benefit through potential use of REGN1979
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.